Skye Bioscience Unveils Presentation on Nimacimab for Obesity and Metabolic Disease Treatment
I'm PortAI, I can summarize articles.
Skye Bioscience Inc. has presented details on nimacimab, a CB1-inhibiting antibody aimed at treating obesity and metabolic diseases. The presentation reveals that nimacimab, when combined with GLP-1 therapies, resulted in a 13% weight loss over 26 weeks, outperforming semaglutide alone. It also showed a favorable safety profile and body composition in a Phase 2a study. The company plans a Phase 2b adaptive design dose-ranging study and is exploring both combination and monotherapy options.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments